Efficacy and cost-benefit of filgrastim administered after early assessment bone marrow biopsy during induction therapy for acute myeloid leukemia-Reference-Cited by-同舟云学术

Efficacy and cost-benefit of filgrastim administered after early assessment bone marrow biopsy during induction therapy for acute myeloid leukemia

Published:2021-01-18 Issue:6 Volume:62 Page:1450-1457
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Wang Jiasheng¹^ORCID,de Lima Marcos¹,Cooper Brenda W.¹,Boughan Kirsten¹,Metheny Leland¹,Otegbeye Folashade¹,Caimi Paolo F.¹,Gallogly Molly¹,Malek Ehsan¹,Cao Shufen¹,Fu Pingfu¹,Glotzbecker Brett¹,Schiltz Nicholas K.²,Tomlinson Benjamin K.¹^ORCID

Affiliation:

1. Seidman Cancer Center, University Hospitals Cleveland Medical Center, Cleveland, OH, USA

2. Francis Payne School of Nursing, Case Western Reserve University, Case Western Reserve University, Cleveland, OH, USA

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1864350

Reference29 articles.

1. The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapy

2. Growth factors in acute myeloid leukaemia